Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Respiratory (Paediatric)
  6. Eradication of Burkholderia Species in Children with Cystic Fibrosis, Paediatrics (700)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Eradication of Burkholderia Species in Children with Cystic Fibrosis, Paediatrics (700)

Disclaimer:

The following guideline has been developed for use within the Royal Hospital for Children, NHS Greater Glasgow and Clyde (NHSGGC).   The guideline has been developed in collaboration with key stakeholders within NHSGGC, including Mircobiology, Cystic Fibrosis, Infectious Disease and Pharmacy teams.  The guideline has been approved by the Paediatric Antimicrobial Management Team and ratified by the NHSGGC Antimicrobial Utilisation Committee.

The guideline does not account for epidemiology and resistance patterns outside of NHS GGC and use outside of the designated organisation is at the individual’s risk. 

Background:

The Burkholderia cepacia complex (Bcc) consists of a group of genomic species called genomovars.  Some examples include B. cepacia, B.multivorans, B. cenocepacia, B.vietnamiensis, B. stabalis, B. dolosa and B. pseudomultivorans.  Reports have confirmed some strains as conferring an adverse prognosis, and colonisation with B. cenocepacia is one of the exclusion criteria from many transplant programmes.

As with P. aeruginosa, some isolates of Bcc, particularly B. multivorans, can be successfully eradicated with early aggressive antibiotic therapy before chronic infection becomes established (Etherington et al, 2003).) While a COCHRANE review in 2019 did not identify any studies of sufficient quality to draw conclusions regarding specific regimes for eradication of Burkholderia and acknowledged a paucity of evidence base, the CF Trust guidelines recommend eradication attempts should be considered. The aim is to prevent chronic colonisation and subsequent impairment of lung function and is routine in many centres based on cases studies and series.  Primary eradication therapy involves a combination of intravenous antibiotics.  Choice is based on culture and sensitivity results (including genome typing) and this therapy is given for a minimum of two weeks, followed by three consecutive months of nebulised TOBI®.  

It may be appropriate to start antibiotic therapy whilst awaiting confirmation as even if Burkholderia species are not identified, it is likely another gram negative organism (e.g Pseudomonas spp) will be identified.

Audit of this protocol shows a high level of success in eradication with currently only ~ 3.5% patients colonised with BCC. This prevalence has remained stable for many years and is in line with UK CF Registry data.

It will be important to monitor the situation as modulator drugs are more widely used and the risk benefit of antibiotics may change.

ERADICATION PATHWAY

Drug monographs

Intravenous drug dosing:

Drug

Dose

Frequency

Comments

Meropenem

40mg/kg (max 2 grams)

Every 8 hours

Consider administration as a prolonged IV infusion (over 3 hours) to achieve a more favourable pK profile.

Tobramycin

10mg/kg (max 660mg)

Once daily

Infuse over 30 minutes.

Level immediately prior to second dose. 

  • If >1mg/L OMIT next dose and re-measure.  Consider extended dosing intervals or reduce dose by 20%.  Repeat levels after 2 days.
  • If level ≤1mg/L, continue and repeat level immediately before day 8 dose.

Oral N-acetylcysteine should be prescribed with each course of IV tobramycin.

N-Acetylcysteine (NAC) for the prevention of aminoglycoside associated ototoxicity in children with cystic fibrosis

For dosing of alternative IV agents please refer to BNF-c, or contact Microbiology or Pharmacy for advice.

Nebulised drug dosing:

Drug

Dose

Frequency

Comments

Tobramycin

≥6 months – 2 years: 150mg

≥ 2 years: 300mg

 

Twice daily

Caution when switching between TOBI/Tymbrineb and Bramitob as solutions are different strengths.

Use in children <6years is unlicensed.

Alternative agents for nebulisation include aztreonam lysine, ceftazidime, meropenem and temocillin – Consultant Microbiology approval required.  For dosing advice following approval please contact Pharmacy.  Burkholderia cepacia complex spp are intrinsically resistant to colistin.

Aminoglycoside Ototoxicity Genetics Testing

If A1555G genetic testing has not been carried out, parents/ patients should  be provided with information about this and if consent obtained, blood should be sent for analysis. If the A1555G mutation is identified, the risks and benefits of continuing aminoglycoside treatment will be discussed and, where possible, alternative treatments will be considered.

Evaluation

ANNUAL AUDIT OF:

  • BURKHOLDERIA ACQUISITION RATE
  • BURKHOLDERIA ERADICATION RATE
  • ONGOING ASSESSMENT OF SERIOUS DRUG RELATED SIDE EFFECTS

Editorial Information

Last reviewed: 01/06/2022

Next review date: 31/05/2025

Author(s): Dr Jane Wilkinson – Associate Specialist, Paediatric Cystic Fibrosis; Dr Christine Peters – Consultant Microbiologist; Dr Rosie Hague – Consultant Paediatric Immunology and Infectious Disease; Susan Kafka – Specialist Pharmacist RHC.

Version: 2

Approved By: Paediatric Drugs & Therapeutics Committee

Document Id: 699

References
  1. Horsley A, Webb K, Bright-Thomas R, Govan J, Jones A. Can Early Burkholderia Cepacia Complex Infection In Cystic Fibrosis Be Eradicated With Antibiotic Therapy?. Front Cell Infect Microbiol. 2011;1:18. Published 2011
  2. “Intravenous Antibiotic Guidelines for Patients with Cystic Fibrosis at Leeds Cystic Fibrosis Units (Adult and Paediatric)”, The Leeds Centre for Cystic Fibrosis and Leed’s Children’s Hospital; Last revised December 2019
  3. Leeds Paediatric CF Unit: The Leeds Method Of Management. April, 2008.
  4. Clinical Guidelines: Care of Children with cystic Fibrosis, 2020; Royal Brompton and Harefield Hospitals NHS Trust.
  5. “Antibiotic Treatment for cystic fibrosis”; The UK Cystic Fibrosis Trust Antibiotic Working Group, Third Edition, May 2009.
  6. WEST OF SCOTLAND ADULT CF UNIT 2015- BURKHOLDERIA ERADICATION PROTOCOL 20187. Tobramycin (Inhaled) monograph – Paediatric; Children’s Antimicrobial Management Program (ChAMP); Perth Children’s Hospital
  7. Garcia, B.A., Carden, J.L., Goodwin, D.L. et al. Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients. BMC Pulm Med 18, 35 (2018). https://doi.org/10.1186/s12890-018-0594-8
  8. Regan, Kate H., and Jayesh Bhatt. "Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis." Cochrane Database of Systematic Reviews 4 (2019).